US Patent

US11878049 — Mitapivat therapy and modulators of cytochrome P450

Method of Use · Assigned to Agios Pharmaceuticals Inc · Expires 2041-07-31 · 15y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating pyruvate kinase deficiency, sickle cell disease, or thalassemia with mitapivat or a pharmaceutically acceptable salt thereof.

USPTO Abstract

Described herein are methods of treating pyruvate kinase deficiency (PKD), sickle cell disease or thalassemia with mitapivat or a pharmaceutically acceptable salt thereof, or use of the drug for the treatment of these conditions, in combination with or in the absence of with a secondary drug, such as an inducer or an inhibitor of cytochrome P450. Various doses and dosing regimens of mitapivat in monotherapy and in concomitant medications are described.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3782 — mitapivat-sulfate
U-3782 — mitapivat-sulfate
U-3782 — mitapivat-sulfate
U-4390 — mitapivat-sulfate

Patent Metadata

Patent number
US11878049
Jurisdiction
US
Classification
Method of Use
Expires
2041-07-31
Drug substance claim
No
Drug product claim
No
Assignee
Agios Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.